Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Bachem Holding AG    BANB   CH0012530207

BACHEM HOLDING AG

(BANB)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Bachem Holding AG : There is still some upside potential

04/07/2021 | 02:59am EDT
long trade
Live
Entry price : 420CHF | Target : 480CHF | Stop-loss : 390CHF | Potential : 14.29%
Shares in Bachem Holding AG show a positive technical chart pattern over the medium term, which suggests that the rising trend should be followed.
Investors have an opportunity to buy the stock and target the CHF 480.
Bachem Holding AG : Bachem Holding AG : There is still some upside potential
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.

Strengths
  • Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 65% by 2023.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Historically, the company has been releasing figures that are above expectations.
  • Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • For the last week, the earnings per share forecast has been revised upwards. According to recent estimates, analysts give a positive overview of the stock
  • For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
  • For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
  • Within the weekly time frame the stock shows a bullish technical configuration above the support level at 321 CHF

Weaknesses
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 58.83 times its estimated earnings per share for the ongoing year.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart
Subsector Other Biotechnology & Medical Research
1st jan.Capitalization (M$)Investor Rating
BACHEM HOLDING AG12.52%6 626
MODERNA, INC.53.18%64 032
LONZA GROUP AG-2.32%45 285
IQVIA HOLDINGS INC.19.51%41 063
CELLTRION, INC.-13.79%37 856
SEAGEN INC.-14.56%27 131
INCYTE CORPORATION-5.48%18 291
HANGZHOU TIGERMED CONSULTIN..-15.04%17 971
PHARMARON BEIJING CO., LTD.22.61%17 460
ALNYLAM PHARMACEUTICALS, IN..6.96%16 310
BIO-TECHNE CORPORATION30.74%16 108
More Results

© MarketScreener.com 2021

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials
Sales 2021 475 M 516 M 516 M
Net income 2021 100 M 109 M 109 M
Net Debt 2021 144 M 157 M 157 M
P/E ratio 2021 62,2x
Yield 2021 0,79%
Capitalization 6 111 M 6 626 M 6 639 M
EV / Sales 2021 13,2x
EV / Sales 2022 11,3x
Nbr of Employees 1 475
Free-Float 42,9%
Upcoming event on BACHEM HOLDING AG
04/28/21
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 483,00 CHF
Last Close Price 445,00 CHF
Spread / Highest target 22,2%
Spread / Average Target 8,54%
Spread / Lowest Target -11,2%
EPS Revisions
Managers and Directors
NameTitle
Thomas Meier Chief Executive Officer
Alain Schaffter Chief Financial Officer
Kuno Sommer Chairman
Günther Loidl Chief Technology Officer
Roland Schürmann Chief Operating Officer